Displaying 1 - 10 of 16 for Cancer - Breast
  • ALTERNATE Study (H-35396)
    • The study is being conducted to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing.
  • CADENCE Study (H-36960)
    • The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
  • Cisplatin vs Paclitaxel for Triple Negative Breast Cancer (H-34421)
    • This research study is evaluating how well triple negative breast cancer responds to preoperative treatment with Cisplatin or Paclitaxel chemotherapy, and if use of a research test can predict response to preoperative treatment.
  • CRIZENT Study (H-33624)
    • CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer - In this study the investigators will be combining both of these two treatments, but at different doses.
  • ICare: Improving Care for Cancer Survivors (H-43629)
    • This study addresses the need to clarify system, provider and survivor-level facilitators of survivorship care plans implementation/use to guide future rollout efforts.
  • METRIC Study (H-34400)
    • Patients with "Triple Negative Breast Cancer" that are gpNMB over-expressing are invited to participate in a new drug study to see if CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients with this diagnosis.
  • NCI MATCH Screening Trial (H-37222)
    • This clinical trial studies how well treatment directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.
  • Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer (H-36359)
    • This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
  • PALLAS Study (H-39113)
    • The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • PALLET Study (H-36507)
    • This study will look at effects the combination of palbociclib and letrozole may have on estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer tumors which have not yet been treated.